vs
Day One Biopharmaceuticals, Inc.（DAWN）与La Rosa Holdings Corp.（LRHC）财务数据对比。点击上方公司名可切换其他公司
Day One Biopharmaceuticals, Inc.的季度营收约是La Rosa Holdings Corp.的2.0倍（$39.8M vs $20.2M），La Rosa Holdings Corp.净利率更高（-27.4% vs -49.6%，领先22.2%），La Rosa Holdings Corp.同比增速更快（3.2% vs -57.6%）
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
拉罗萨控股旗下的万拉罗萨父子通心粉公司由西西里移民文森佐·拉罗萨于1914年创立，发展至今已成为美国规模领先的区域知名食品品牌，可生产四十余种意面产品，在当地市场拥有较高的认可度。
DAWN vs LRHC — 直观对比
营收规模更大
DAWN
是对方的2.0倍
$20.2M
营收增速更快
LRHC
高出60.7%
-57.6%
净利率更高
LRHC
高出22.2%
-49.6%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.8M | $20.2M |
| 净利润 | $-19.7M | $-5.5M |
| 毛利率 | — | 8.4% |
| 营业利润率 | -60.9% | -24.7% |
| 净利率 | -49.6% | -27.4% |
| 营收同比 | -57.6% | 3.2% |
| 净利润同比 | -153.3% | -125.7% |
| 每股收益（稀释后） | $-0.19 | $-5.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DAWNLRHC
| Q3 25 | $39.8M | $20.2M | ||
| Q2 25 | $33.9M | $23.2M | ||
| Q1 25 | $30.8M | $17.5M | ||
| Q4 24 | — | $17.7M | ||
| Q3 24 | $93.8M | $19.6M | ||
| Q2 24 | — | $19.1M | ||
| Q1 24 | $0 | $13.1M | ||
| Q3 23 | $0 | $6.8M |
净利润DAWNLRHC
| Q3 25 | $-19.7M | $-5.5M | ||
| Q2 25 | $-30.3M | $78.4M | ||
| Q1 25 | $-36.0M | $-95.7M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | $37.0M | $-2.5M | ||
| Q2 24 | — | $-2.3M | ||
| Q1 24 | $-62.4M | $-4.6M | ||
| Q3 23 | $-46.1M | $-343.8K |
毛利率DAWNLRHC
| Q3 25 | — | 8.4% | ||
| Q2 25 | — | 8.0% | ||
| Q1 25 | — | 8.8% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | — | 8.3% | ||
| Q2 24 | — | 8.3% | ||
| Q1 24 | — | 8.9% | ||
| Q3 23 | — | 8.5% |
营业利润率DAWNLRHC
| Q3 25 | -60.9% | -24.7% | ||
| Q2 25 | -103.1% | -10.6% | ||
| Q1 25 | -133.5% | -26.7% | ||
| Q4 24 | — | -17.1% | ||
| Q3 24 | 31.6% | -8.9% | ||
| Q2 24 | — | -9.7% | ||
| Q1 24 | — | -35.0% | ||
| Q3 23 | — | -6.1% |
净利率DAWNLRHC
| Q3 25 | -49.6% | -27.4% | ||
| Q2 25 | -89.4% | 337.8% | ||
| Q1 25 | -117.0% | -546.5% | ||
| Q4 24 | — | -28.7% | ||
| Q3 24 | 39.5% | -12.5% | ||
| Q2 24 | — | -12.2% | ||
| Q1 24 | — | -35.1% | ||
| Q3 23 | — | -5.1% |
每股收益（稀释后）DAWNLRHC
| Q3 25 | $-0.19 | $-5.44 | ||
| Q2 25 | $-0.29 | $15.25 | ||
| Q1 25 | $-0.35 | $-5.86 | ||
| Q4 24 | — | $28.54 | ||
| Q3 24 | $0.38 | $-16.49 | ||
| Q2 24 | — | $-12.49 | ||
| Q1 24 | $-0.72 | $-0.35 | ||
| Q3 23 | $-0.54 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $451.6M | $4.0M |
| 总债务越低越好 | — | $642.8K |
| 股东权益账面价值 | $450.9M | $1.6M |
| 总资产 | $513.8M | $21.7M |
| 负债/权益比越低杠杆越低 | — | 0.41× |
8季度趋势，按日历期对齐
现金及短期投资DAWNLRHC
| Q3 25 | $451.6M | $4.0M | ||
| Q2 25 | $453.1M | $5.1M | ||
| Q1 25 | $473.0M | $2.9M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | $558.4M | $1.8M | ||
| Q2 24 | — | $1.6M | ||
| Q1 24 | $317.9M | $1.1M | ||
| Q3 23 | $405.5M | $350.3K |
总债务DAWNLRHC
| Q3 25 | — | $642.8K | ||
| Q2 25 | — | $644.3K | ||
| Q1 25 | — | $645.9K | ||
| Q4 24 | — | $647.6K | ||
| Q3 24 | — | $649.2K | ||
| Q2 24 | — | $650.8K | ||
| Q1 24 | — | $652.4K | ||
| Q3 23 | — | — |
股东权益DAWNLRHC
| Q3 25 | $450.9M | $1.6M | ||
| Q2 25 | $460.8M | $3.4M | ||
| Q1 25 | $479.5M | $-87.5M | ||
| Q4 24 | — | $2.6M | ||
| Q3 24 | $555.5M | $5.0M | ||
| Q2 24 | — | $4.7M | ||
| Q1 24 | $296.8M | $5.6M | ||
| Q3 23 | $389.6M | $722.5K |
总资产DAWNLRHC
| Q3 25 | $513.8M | $21.7M | ||
| Q2 25 | $519.0M | $22.9M | ||
| Q1 25 | $534.4M | $21.0M | ||
| Q4 24 | — | $19.4M | ||
| Q3 24 | $600.8M | $19.7M | ||
| Q2 24 | — | $18.7M | ||
| Q1 24 | $326.6M | $16.3M | ||
| Q3 23 | $414.2M | $5.8M |
负债/权益比DAWNLRHC
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.12× | ||
| Q3 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.8M | $-1.3M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DAWNLRHC
| Q3 25 | $-5.8M | $-1.3M | ||
| Q2 25 | $-24.8M | $-1.4M | ||
| Q1 25 | $-59.0M | $-3.5M | ||
| Q4 24 | — | $-1.1M | ||
| Q3 24 | $50.8M | $-591.6K | ||
| Q2 24 | — | $-803.1K | ||
| Q1 24 | $-49.7M | $-538.3K | ||
| Q3 23 | $-37.1M | — |
自由现金流DAWNLRHC
| Q3 25 | — | — | ||
| Q2 25 | $-24.8M | — | ||
| Q1 25 | $-59.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $50.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | $-37.1M | — |
自由现金流率DAWNLRHC
| Q3 25 | — | — | ||
| Q2 25 | -73.2% | — | ||
| Q1 25 | -192.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
资本支出强度DAWNLRHC
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
现金转化率DAWNLRHC
| Q3 25 | — | — | ||
| Q2 25 | — | -0.02× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
LRHC
| Real Estate Residential Brokerage Services | $16.8M | 83% |
| Transferred Over Time | $3.5M | 17% |
